imatinib mesylate has been researched along with Cell Transformation, Neoplastic in 95 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (2.11) | 18.2507 |
| 2000's | 61 (64.21) | 29.6817 |
| 2010's | 30 (31.58) | 24.3611 |
| 2020's | 2 (2.11) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel Hamid, M; Aref, S; Ayed, M; El-Sokkary, AMA; Fathy El-Metwaly, N | 1 |
| Chen, B; Guan, J; Ma, J | 1 |
| Chen, C; Fu, Y; Huang, T; Wang, S; Wang, X; Xu, M; Yin, X; Zhou, M | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Dębiec-Rychter, M; Jagielska, B; Klimczak, A; Pieńkowska-Grela, B; Rutkowski, P; Świtaj, T; Wągrodzki, M; Ługowska, I | 1 |
| Feng, W; Gao, M; Huang, N; Huang, Z; Liu, L; Luo, Z; Wang, X; Xiao, Q; Zhou, F | 1 |
| Almeida, AM; Alves, R; Freitas-Tavares, P; Gonçalves, AC; Jorge, J; Luís, D; Marques, G; Oliveiros, B; Ribeiro, AB; Sarmento-Ribeiro, AB | 1 |
| Ayoubi, HR; Bazarbachi, AA; Bitar, NM; De Thé, HB; El Eit, RM; Iskandarani, AN; Jabbour, MN; Mahfouz, RA; Mahon, FX; Nasr, RR; Saliba, JL; Zaatari, GS | 1 |
| Chen, JL; Chen, Q; Chen, R; Chen, Y; Guo, G; Huang, S; Kang, Q; Ouyang, J; Tan, H; Wang, X; Zhang, L; Zhu, X | 1 |
| Agopian, J; Bertucci, F; Chauvot de Beauchêne, I; De Sepulveda, P; Dubreuil, P; Fouet, B; Fournier, B; Mescam-Mancini, L; Panel, N; Tchertanov, L; Tisserand, JC; Vita, M | 1 |
| Chen, C; Chen, JL; Chen, K; Chen, Q; Guo, G; Huang, S; Li, F; Nalepa, G; Wang, S | 1 |
| Amin, A; Aslam, HM; Bashir, S; Hashmi, AS; Malik, B; Mumtaz, S; Tariq, M | 1 |
| Arts, FA; Chand, D; Constantinescu, S; Demoulin, JB; Hallberg, B; Pecquet, C; Velghe, AI | 1 |
| Deininger, MW; Druker, BJ; Honigberg, LA; MacPartlin, M; Smith, AM | 1 |
| Bullinger, L; Chen, J; Fröhling, S; Gilliland, DG; Golub, TR; Gu, TL; Lee, BH; Monti, S; Tam, WF; Wang, A | 1 |
| Berdel, WE; Choudhary, C; Evers, G; Hehn, S; Müller-Tidow, C; Ng, PR; Sargin, B; Serve, H; Tickenbrock, L | 1 |
| Druker, BJ; Fan, HY; Fruehauf, J; Fu, W; Gram, H; Kim, JW; Ko, J; Moore, JC; Ong, ST; Prabhu, S; Trapp, V; Zhang, M | 1 |
| Albini, A; Ambrosini, C; Fassina, G; Ferrari, N; Frassoni, F; Monteghirfo, S; Pozzi, S; Soverini, S; Stigliani, S; Tosetti, F | 1 |
| DeGeer, D; Jiang, X; Kennah, E; Li, XJ; Lin, AE; Ringrose, A; Sheng, G; Turhan, A; Zhao, Y; Zhou, LL | 1 |
| Crawford, LJ; Irvine, AE; Magill, L; McCallum, L; McMullin, MF; Melo, JV; Ovaa, H; Walker, B; Windrum, P | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Champlin, R; Cortés, JE; de Lima, M; Fisher, T; Giralt, S; Hosing, C; Jabbour, E; Kantarjian, H; Kebriaei, P; Popat, U; Qazilbash, M; Rondon, G; Shpall, E | 1 |
| Arai, A; Kurosu, T; Miura, O; Murakami, N; Oshikawa, G | 1 |
| Allis, CD; Antonescu, CR; Chen, Y; Chi, P; Dewell, S; Fletcher, JA; Guo, X; Maki, RG; Sawyers, CL; Shamu, T; Wongvipat, J; Zhang, L; Zheng, D | 1 |
| Corless, CL; Heinrich, MC | 1 |
| Cheng, D; Colicelli, J; McLaughlin, J; Müschen, M; Thai, M; Ting, PY; Witte, ON | 1 |
| Berdel, WE; Cross, NC; Elling, C; Erben, P; Frickenhaus, M; Hochhaus, A; Hofmann, WK; Koschmieder, S; Müller-Tidow, C; Reiter, A; Schemionek, M; Serve, H; Stehling, M; Walz, C | 1 |
| Bauer, J; Eigentler, TK; Garbe, C; Held, L; Held, M; Meier, F; Röcken, M | 1 |
| Basu, S; Luong, P; Man, YK; Melo, JV; Nteliopoulos, G; Sears, D; Yuan, M | 1 |
| Liang, R; Rubin, BP; Schadendorf, D; Wallace, AR | 1 |
| Green, MR; Ma, L; Sheng, Z; Sun, JE; Zhu, LJ | 1 |
| Aulitzky, WE; Dengler, MA; Doszczak, M; Gutekunst, M; Hofmann, U; Scheurich, P; Schwab, M; Staiger, AM; van der Kuip, H | 1 |
| Bhatia, R; Chen, WY; Roth, M; Wang, Z; Yuan, H; Zhang, H | 1 |
| Bosenberg, M; Curley, DP; Damsky, WE; Dankort, D; Gould Rothberg, BE; McMahon, M; Platt, JT; Rimm, DL; Rosenbaum, LE; Santhanakrishnan, M; Taketo, MM | 1 |
| Bhatia, R; Chen, W; Horne, D; Li, L; Modi, H; Wang, Z; Yuan, H; Zhang, H | 1 |
| Esmailzadeh, S; Jiang, X | 1 |
| Chau, WK; Ip, CK; Lai, HC; Mak, AS; Wong, AS | 1 |
| Deng, Z; Dong, Y; Han, Q; Jiang, T; Jin, H; Lu, X; Ren, H; Su, J; Wang, X; Zhang, W; Zou, Y | 1 |
| Alpár, D; de Jong, D; Kajtár, B; Kereskai, L; Pajor, L; Savola, S; Szuhai, K; Yigittop, H | 1 |
| Bi, C; Cheong, LL; Chng, WJ; Chong, PS; Liu, SC; Mahara, S; Ong, KO; Zeng, Q; Zhou, J | 1 |
| Aberger, F; Antonescu, CR; Beissbarth, T; Binder, C; Bleckmann, A; Dittmann, K; Dressel, R; Gruber, W; Guijarro, MV; Hahn, H; Heijmans, J; Hernando, E; Hogendoorn, PC; Nitzki, F; Pelczar, P; Rubin, BP; Schulz-Schaeffer, W; Taguchi, T; Uhmann, A; van den Brink, GR; van Dop, WA; Wienands, J; Wojnowski, L; Zibat, A | 1 |
| Boulton, C; Fabbro, D; Gilliland, DG; Griffin, JD; Kelly, LM; Manley, P; Meyer, T; Weisberg, E | 1 |
| Gesbert, F; Griffin, JD; Gu, H; Iwasaki, H; Li, S; Malouf, NA; Mohi, MG; Neel, BG; Podar, K; Pride, YB; Quinnan, LR; Sattler, M; Van Etten, RA | 1 |
| Bell, YC; Druker, BJ; Früh, K; Griffith, DJ; Heinrich, MC; Jarvis, MA; Luukkonen, BG; Moses, AV; Nelson, JA; Raggo, C; Ruhl, R; Wait, CL | 2 |
| Losonczy, H; Molnár, L | 1 |
| Goldberg, SL; Hsu, JW; Madan, RA; Pecora, AL; Rowley, SD; Tantravahi, R | 1 |
| Estrov, Z; Ravandi, F; Talpaz, M | 1 |
| Biondi, A; Cazzaniga, G; Gambacorti-Passerini, C; Gunby, RH; Le Coutre, P; Pogliani, E; Specchia, G; Tassi, E | 1 |
| Briesewitz, R; Bruner, RJ; Caligiuri, MA; Griffin, JH; Leung, J | 1 |
| Beissert, T; Bianchini, A; Boehrer, S; Güller, S; Hoelzer, D; Nervi, C; Ottmann, OG; Puccetti, E; Ruthardt, M | 1 |
| Calame, K; Kong, HJ; Ozato, K; Tamura, T; Tsujimura, H; Tunyaplin, C | 1 |
| Burchert, A; Cai, D; Duyster, J; Eilers, M; Hochhaus, A; Hofbauer, LC; Müller, R; Neubauer, A; Ritter, M; Samuelsson, MK; Schmidt, M; Slater, EP | 1 |
| Haydon, RC; He, TC; Zhou, L | 1 |
| Van Etten, RA | 1 |
| Apperley, JF; Avery, S; Brito Babapulle, F; Goldman, JM; Kaeda, J; Marin, D; Nadal, E; Olavarria, E; Vulliamy, T | 1 |
| Duensing, A; Fletcher, CD; Fletcher, JA; Heinrich, MC | 1 |
| Auclair, C; Calipel, A; Glotin, AL; Kherrouche, Z; Lefevre, G; Mascarelli, F; Maurage, CA; Mouriaux, F; Tran, T | 1 |
| Cools, J; Gilliland, G; Marynen, P; Stover, EH; Wlodarska, I | 1 |
| Chen, J; Duclos, N; Fabbro, D; Gilliland, DG; Griffin, JD; Kocher, K; Neuberg, D; Shi, Y; Wall, NR | 1 |
| Feldhahn, N; Klein, F; Müschen, M | 1 |
| Bhatia, R; Chu, S; Holtz, M; Niu, N; Ramaraj, P; Singh, H; Yee, JK | 1 |
| Corless, CL; Fletcher, JA; Heinrich, MC | 1 |
| Babendreier, E; Chauhan, D; Chu, SC; Gramlich, JL; Griffin, JD; Kim, JH; Podar, K; Pride, YB; Salgia, R; Sattler, M | 1 |
| Gilliland, DG; Lu, Y; Pierce, A; Sternberg, DW; Unwin, RD; Whetton, AD | 1 |
| Limnander, A; Niki, M; Oki, S; Pandolfi, PP; Rothman, PB; Yao, PM | 1 |
| Bikfalvi, A; de Lafarge, B; Eichmann, A; Gilges, D; Hagedorn, M; Javerzat, S; Meyre, A | 1 |
| Alani, R; Arbiser, JL; Arnold, RS; Chung, J; Cohen, C; Cuezva, JM; Fan, CY; Govindarajan, B; Martinez, M; Mercurio, AM; Ryu, B; Schechner, J; Shah, A | 1 |
| Andersen, MK; Brondum-Nielsen, K; Dufva, IH; Johnsen, HE; Karle, H; Madsen, HO | 1 |
| Ren, R | 1 |
| Dusková, M; Jelínek, F; Ludvíková, V; Marinov, I; Petrácková, M; Smetana, K; Sobotkova, E; Vonka, V | 1 |
| Arnoletti, JP; Birbe, R; Canutescu, AA; Dunbrack, R; Eisenberg, B; Godwin, AK; Heslin, MJ; Merkel, E; Patchefsky, A; Shen, W; Skorobogatko, Y; Tarn, C; von Mehren, M | 1 |
| Fay, M; Goldman, J; Murphy, PT; O'Donnell, R; Quinn, J; Swords, R | 1 |
| Berman, E; Bhalla, K; Copelan, EA; Devetten, MP; Emanuel, PD; Erba, HP; Greenberg, PL; Moore, JO; O'Brien, S; Przepiorka, D; Radich, JP; Schilder, RJ; Shami, P; Smith, BD; Snyder, DS; Soiffer, RJ; Tallman, MS; Talpaz, M; Wetzler, M | 1 |
| Helbig, G; Hołowiecki, J; Stella-Hołowiecka, B | 1 |
| Bargo, S; Callahan, R; Kimura, K; Raafat, A; Salomon, D; Strizzi, L; Zoltan-Jones, A | 1 |
| Bumm, T; Corbin, AS; Deininger, MW; Druker, BJ; Goss, VL; Griswold, IJ; Johnson, K; Lee, KA; MacPartlin, M; Moseson, EM; O'Hare, T; Polakiewicz, RD; Smith, C; Stoffregen, EP; Wood, LJ | 1 |
| Blay, JY | 1 |
| Gouilleux, F; Lassoued, K; Murakami, H; Nyga, R; Pecquet, C; Penard-Lacronique, V; Régnier, A; Smithgall, TE | 1 |
| Bouillet, P; Cragg, MS; Druker, BJ; Huang, DC; Kelly, PN; Kimura, S; Kuroda, J; Ottmann, OG; Puthalakath, H; Roberts, AW; Strasser, A; Villunger, A | 1 |
| Duffy, TM; Hu, Y; Lee, FY; Li, S; Swerdlow, S; Weinmann, R | 1 |
| Sell, S | 1 |
| Chang, ZF; Kuo, YY | 1 |
| Borneo, J; Chan, RJ; Kapur, R; Munugalavadla, V; Sims, EC | 1 |
| Erben, P; Fabarius, A; Frank, O; Giehl, M; Hafner, M; Hehlmann, R; Hochhaus, A; Seifarth, W; Zheng, C | 1 |
| Bhatia, R; Chu, S; Li, L; Singh, H | 1 |
| Alpers, CE; Bauer, RL; Campbell, JS; Fausto, N; Gilbertson, DG; Hudkins, KL; Johnson, MM; Riehle, KJ; Yeh, MM | 1 |
| Chen, JL; Limnander, A; Rothman, PB | 1 |
| Battmer, K; Breyer, B; Eder, M; Kardinal, C; Koch, A; Mancini, A; Scherr, M; Tamura, T | 1 |
| Buchdunger, E; Collins, VP; Dumanski, JP; Heldin, CH; O'Brien, KP; Ostman, A; Pietras, K; Shimizu, A; Sjöblom, T | 1 |
| Algate, PA; Byrne, CH; Griffin, JD; Rohrschneider, LR; Sattler, M; Shrikhande, G; Verma, S; Winkler, T | 1 |
| Gilliland, DG; Griffin, JD; Okuda, K; Weisberg, E | 1 |
| Cleris, L; Formelli, F; Greco, A; Miranda, C; Pierotti, MA; Roccato, E | 1 |
| Griffin, JD; Sattler, M | 1 |
| Jahagirdar, BN; Miller, JS; Shet, A; Verfaillie, CM | 1 |
| Hasselbalch, HC | 1 |
19 review(s) available for imatinib mesylate and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
De nove Philadelphia chromosome-positive myelodysplastic syndromes with complex karyotype and p230
Topics: Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Philadelphia Chromosome | 2023 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.
Topics: Adult; Aged; Benzamides; Cell Transformation, Neoplastic; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Outcome | 2009 |
Oncogenetics of melanoma: basis for molecular diagnostics and therapy.
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; DNA Mutational Analysis; Drugs, Investigational; Humans; Imatinib Mesylate; Melanoma; Molecular Targeted Therapy; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Skin Neoplasms | 2011 |
AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Animals; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia; Lymphoma; Mice; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Piperazines; Pyrimidines | 2011 |
[Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2002 |
Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Drug Design; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Signal Transduction | 2003 |
Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era.
Topics: Benzamides; Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Signal Transduction | 2004 |
Biology of gastrointestinal stromal tumors: KIT mutations and beyond.
Topics: Benzamides; Cell Transformation, Neoplastic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Stromal Cells | 2004 |
FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Enzyme Inhibitors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Mastocytosis, Systemic; Mice; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Oncogenes; Piperazines; Pyrimidines; Radiation Chimera; Receptor, Platelet-Derived Growth Factor alpha; Xenograft Model Antitumor Assays | 2004 |
Interference of BCR-ABL1 kinase activity with antigen receptor signaling in B cell precursor leukemia cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Survival; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Granulocyte Precursor Cells; Humans; Imatinib Mesylate; Leukemia, B-Cell; Piperazines; Pyrimidines; Receptors, Antigen, B-Cell; Signal Transduction | 2004 |
Biology of gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Mutation; Oncogenes; Phenotype; Phosphotransferases; Piperazines; Prognosis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stromal Cells | 2004 |
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Oncogene Proteins v-abl; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines | 2005 |
[Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy].
Topics: Algorithms; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chronic Disease; Dose-Response Relationship, Drug; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2005 |
[Targeted therapies of cancer: not lost in translation].
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mutation; Neoplasm Proteins; Neoplasms; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Leukemia: stem cells, maturation arrest, and differentiation therapy.
Topics: Antineoplastic Agents; Benzamides; Cell Differentiation; Cell Transformation, Neoplastic; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myeloid; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2005 |
Mechanisms of transformation by the BCR/ABL oncogene.
Topics: Benzamides; Cell Transformation, Neoplastic; Cytoskeleton; Enzyme Activation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Oncogene Proteins, Fusion; Philadelphia Chromosome; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Protein Structure, Tertiary; Protein Transport; Pyrimidines; Reactive Oxygen Species; Signal Transduction | 2001 |
Novel therapies for chronic myelogenous leukemia.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Cancer Vaccines; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Genes, myb; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Models, Biological; Multicenter Studies as Topic; Neoplasm Proteins; Oligonucleotides, Antisense; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Tetrahydrofolate Dehydrogenase | 2001 |
[STI571 (Glivec)--a new drug for the treatment of chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Drug Interactions; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2002 |
1 trial(s) available for imatinib mesylate and Cell Transformation, Neoplastic
76 other study(ies) available for imatinib mesylate and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome.
Topics: Adolescent; ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Biomarkers, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2021 |
miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Topics: 3' Untranslated Regions; Aminopyridines; Base Sequence; Benzamides; Blast Crisis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Down-Regulation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oncogenes; Protein Biosynthesis | 2019 |
Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Topics: Adult; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Dermatofibrosarcoma; Disease-Free Survival; Extremities; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Skin Neoplasms; Soft Tissue Neoplasms; Torso; Treatment Outcome; Young Adult | 2017 |
Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Editing; Genetic Vectors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Recombinational DNA Repair; Sequence Analysis, DNA; Xenograft Model Antitumor Assays; Zinc Finger Nucleases | 2018 |
MicroRNA signature refine response prediction in CML.
Topics: Adult; Aged; Biomarkers, Tumor; Cell Transformation, Neoplastic; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Prognosis; Protein Kinase Inhibitors; Survival Rate; Tumor Cells, Cultured | 2019 |
Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Bone Marrow Transplantation; Cell Transformation, Neoplastic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Oxides; Piperazines; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Survival Rate; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2014 |
A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; DNA Methylation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; HEK293 Cells; Hep G2 Cells; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MCF-7 Cells; Mice; Mice, Nude; Mice, Transgenic; MicroRNAs; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; PTEN Phosphohydrolase; Pyrimidines; RNA, Long Noncoding; RNA, Messenger; Transplantation, Heterologous | 2015 |
Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.
Topics: Aged, 80 and over; Animals; Benzamides; Cell Transformation, Neoplastic; Cells, Cultured; Colony-Forming Units Assay; Dasatinib; Fatal Outcome; Female; Fibroblasts; Humans; Imatinib Mesylate; Lung Neoplasms; Melanoma; Mutation, Missense; Phosphorylation; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines; Rats; Skin Neoplasms; Spinal Neoplasms; Thiazoles | 2014 |
A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis.
Topics: Animals; Carcinogenesis; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor Proteins; Dual-Specificity Phosphatases; Female; Fusion Proteins, bcr-abl; G1 Phase; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; K562 Cells; Mice, Nude; Phosphorylation; S Phase; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2014 |
Orbital dermatofibrosarcoma protuberans with intracranial extension preceded by recurrent leiomyoma of the orbit: a case report.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Combined Modality Therapy; Dermatofibrosarcoma; Eye Neoplasms; Humans; Imatinib Mesylate; Leiomyoma; Male; Middle Aged; Oncogene Proteins, Fusion; Orbit; Skin Neoplasms | 2015 |
PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.
Topics: Animals; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Female; Growth Disorders; Humans; Imatinib Mesylate; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Knockout; Mutagenesis, Site-Directed; Mutation; Myofibromatosis; Neoplasms, Experimental; NIH 3T3 Cells; Oncogenes; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Syndrome | 2016 |
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Benzamides; Cell Transformation, Neoplastic; Cells, Cultured; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Lymphocytes; Mice; Mice, Inbred BALB C; Myeloid Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Gene Expression; HL-60 Cells; Humans; Imatinib Mesylate; Inhibitor of Differentiation Protein 1; K562 Cells; Leukemia; Leukemia, Experimental; Mice; Oncogenes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; RNA, Small Interfering; Signal Transduction | 2008 |
Activation of Wnt signaling in cKit-ITD mediated transformation and imatinib sensitivity in acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; beta Catenin; Cell Line; Cell Transformation, Neoplastic; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Glycogen Synthase Kinase 3; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Mice; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Tandem Repeat Sequences; Transfection; Wnt Proteins | 2008 |
Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.
Topics: Aniline Compounds; Apoptosis; Benzamides; Cell Cycle; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Eukaryotic Initiation Factor-4F; Feedback, Physiological; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinases; Peptide Chain Initiation, Translational; Phosphorylation; Piperazines; Polyribosomes; Protein Kinases; Purines; Pyrimidines; Ribosomal Protein S6; RNA Caps; RNA Transport; RNA, Messenger; Signal Transduction; Substrate Specificity; TOR Serine-Threonine Kinases | 2008 |
Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Adhesion; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endothelial Cells; Extracellular Matrix; Flavonoids; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Invasiveness; Neovascularization, Pathologic; NF-kappa B; Piperazines; Propiophenones; Pyrimidines; Reactive Oxygen Species; Tumor Suppressor Protein p53; U937 Cells; Vascular Endothelial Growth Factor A | 2008 |
AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Benzamides; Blotting, Western; Cell Line; Cell Transformation, Neoplastic; DNA Primers; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Immunoprecipitation; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2008 |
Proteasome proteolytic profile is linked to Bcr-Abl expression.
Topics: Apoptosis; Benzamides; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrimidines; Tumor Cells, Cultured | 2009 |
Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Base Sequence; Benzamides; Bone Marrow; Cell Transformation, Neoplastic; Clone Cells; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Sequence Data; Philadelphia Chromosome; Piperazines; Polyploidy; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Time Factors | 2010 |
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours.
Topics: Animals; Benzamides; Binding Sites; Biomarkers, Tumor; Cell Line, Tumor; Cell Lineage; Cell Survival; Cell Transformation, Neoplastic; Disease Progression; DNA-Binding Proteins; Enhancer Elements, Genetic; Gastrointestinal Stromal Tumors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Mice; Mutant Proteins; Mutation; NIH 3T3 Cells; Oncogenes; Piperazines; Protein Stability; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Transcription Factors | 2010 |
Cancer: Oncogenes in context.
Topics: Animals; Benzamides; Cell Survival; Cell Transformation, Neoplastic; DNA-Binding Proteins; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mutation; Oncogenes; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Transcription Factors | 2010 |
ABL fusion oncogene transformation and inhibitor sensitivity are mediated by the cellular regulator RIN1.
Topics: Animals; Benzamides; Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; K562 Cells; Mice; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src Homology Domains; Translocation, Genetic | 2011 |
Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Separation; Cell Transformation, Neoplastic; Female; Flow Cytometry; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Mice; Piperazines; Point Mutation; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Xenograft Model Antitumor Assays | 2011 |
Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Benzamides; CCAAT-Enhancer-Binding Proteins; Cell Proliferation; Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Mitogen-Activated Protein Kinase Kinases; Phosphopeptides; Phosphorylation; Piperazines; Proteome; Proto-Oncogene Proteins c-akt; Pyrimidines; Ribosomal Protein S6 Kinases, 90-kDa; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured | 2010 |
The phosphatidyl inositol 3-kinase pathway is central to the pathogenesis of Kit-activated melanoma.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Enzyme Activation; Humans; Imatinib Mesylate; Melanocytes; Melanoma; Mice; Models, Biological; Mutant Proteins; Phosphatidylinositol 3-Kinase; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Signal Transduction; Thiazoles | 2011 |
BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
Topics: Activating Transcription Factors; Animals; Antineoplastic Agents; Autophagy; Benzamides; Blotting, Western; Cell Transformation, Neoplastic; Chromatin Immunoprecipitation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luciferases; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; TOR Serine-Threonine Kinases; Transcription, Genetic | 2011 |
Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Fusion Proteins, bcr-abl; Gas Chromatography-Mass Spectrometry; Glucocorticoids; Glycolysis; Imatinib Mesylate; Metabolomics; Mice; Necrosis; Piperazines; Precursor Cells, B-Lymphoid; Pyrimidines; RNA, Small Interfering; Up-Regulation | 2011 |
Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
Topics: Apoptosis; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitosis; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.
Topics: Animals; Antigens, Differentiation; Benzamides; beta Catenin; Cell Transformation, Neoplastic; Colorectal Neoplasms; Enzyme Activation; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Melanocytes; Melanoma, Experimental; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Phosphorylation; Piperazines; Protein Stability; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Signal Transduction; Skin Neoplasms; Splenic Neoplasms; Transcription, Genetic; Tumor Cells, Cultured | 2011 |
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Knockout; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sirtuin 1; STAT5 Transcription Factor; Stress, Physiological; Transcriptional Activation; Transfection | 2012 |
c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; beta Catenin; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA Interference; RNA, Small Interfering; Tumor Microenvironment; Wnt Proteins; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2013 |
Long-term exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells.
Topics: Animals; Benzamides; Cell Differentiation; Cell Line, Tumor; Cell Transformation, Neoplastic; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imatinib Mesylate; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Spheroids, Cellular; Time Factors | 2012 |
MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Child; Clonal Evolution; Cohort Studies; DNA Copy Number Variations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Nucleic Acid Amplification Techniques; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence | 2012 |
The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Metastasis; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein Tyrosine Phosphatases; Pyrimidines; Signal Transduction; STAT Transcription Factors | 2012 |
Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit.
Topics: Animals; Benzamides; Cell Transformation, Neoplastic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gene Expression; Genotype; Hedgehog Proteins; Humans; Imatinib Mesylate; Integrases; Intestinal Mucosa; Kruppel-Like Transcription Factors; Leiomyosarcoma; Mice; Muramidase; Nerve Tissue Proteins; Patched Receptors; Patched-1 Receptor; Piperazines; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Cell Surface; Signal Transduction; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2; Zinc Finger Protein Gli3 | 2013 |
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Bone Marrow Transplantation; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Imatinib Mesylate; Immunoblotting; Interleukin-3; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Phosphorylation; Piperazines; Protein Kinase C; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Staurosporine; Transfection; Tumor Cells, Cultured | 2002 |
Critical role for Gab2 in transformation by BCR/ABL.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Benzamides; Cell Division; Cell Movement; Cell Transformation, Neoplastic; Erythroid Precursor Cells; Fusion Proteins, bcr-abl; GRB2 Adaptor Protein; Guanosine Triphosphate; Helminth Proteins; Humans; Imatinib Mesylate; Immunoblotting; Leukemia, Lymphoid; Mice; Mice, Knockout; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Precipitin Tests; Proteins; Pyrimidines; Signal Transduction; Tyrosine | 2002 |
Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells.
Topics: Base Sequence; Benzamides; Cell Adhesion; Cell Division; Cell Line; Cell Size; Cell Transformation, Neoplastic; Cell Transformation, Viral; DNA; Endothelium, Vascular; Gene Expression Profiling; Herpesvirus 8, Human; Humans; Imatinib Mesylate; Neovascularization, Pathologic; Piperazines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Proto-Oncogenes; Pyrimidines; Sarcoma, Kaposi; Signal Transduction; Stem Cell Factor; Up-Regulation | 2002 |
Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy.
Topics: Benzamides; Cell Lineage; Cell Transformation, Neoplastic; Clone Cells; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Myelodysplastic Syndromes; Piperazines; Pyrimidines | 2003 |
A functional genomics approach to Kaposi's sarcoma.
Topics: Benzamides; Cell Line, Transformed; Cell Transformation, Neoplastic; Cell Transformation, Viral; Endothelium, Vascular; Enzyme Inhibitors; Gene Expression Profiling; Genomics; Herpesvirus 8, Human; Humans; Imatinib Mesylate; Oligonucleotide Array Sequence Analysis; Piperazines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Antisense; Sarcoma, Kaposi; Virulence | 2002 |
Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
Topics: Animals; Benzamides; Cell Line, Transformed; Cell Transformation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Mice; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.
Topics: Adult; Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Benzamides; Blotting, Western; Cell Division; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Eosinophils; Gene Deletion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Indoles; Male; Mice; Models, Chemical; Models, Genetic; Molecular Sequence Data; Peptides; Phthalazines; Piperazines; Precipitin Tests; Protein Structure, Tertiary; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Fusion Proteins; Recurrence; Tyrosine | 2003 |
Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line; Cell Line, Transformed; Cell Transformation, Neoplastic; COS Cells; DNA, Complementary; Fibroblasts; Fusion Proteins, bcr-abl; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia; Mice; Microscopy, Fluorescence; Mutation; Oncogene Proteins; Phosphorylation; Piperazines; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Pyrimidines; Rats; Recombinant Fusion Proteins; Retroviridae; Time Factors | 2003 |
ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells.
Topics: Animals; Benzamides; Cell Differentiation; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Enzyme Inhibitors; Estradiol; Fusion Proteins, bcr-abl; Gene Expression Regulation; Genes, myc; Imatinib Mesylate; Interferon Regulatory Factors; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Myeloid Cells; Piperazines; Positive Regulatory Domain I-Binding Factor 1; Pyrimidines; Receptors, Estrogen; Recombinant Fusion Proteins; Repressor Proteins; RNA, Messenger; Transcription Factors; Transcription, Genetic | 2003 |
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.
Topics: Animals; Apoptosis; Benzamides; Cell Line; Cell Line, Transformed; Cell Transformation, Neoplastic; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon Regulatory Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Multipotent Stem Cells; Piperazines; Promoter Regions, Genetic; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Repressor Proteins; Transfection | 2004 |
Tyrosine kinase inhibitor STI-571: the new wonder drug of cancer therapy.
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chemoprevention; Colorectal Neoplasms; Drug Design; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.
Topics: Aged; Benzamides; Blast Crisis; Cell Transformation, Neoplastic; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Remission Induction | 2004 |
Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis.
Topics: Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Cell Transformation, Neoplastic; DNA Primers; Gene Expression; Humans; Imatinib Mesylate; Melanocytes; Melanoma; Mitogens; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; RNA, Small Interfering; Signal Transduction; Stem Cell Factor; Uvea; Uveal Neoplasms | 2004 |
Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Humans; Imatinib Mesylate; Interleukin-3; Mice; Mice, Inbred BALB C; Mice, Nude; Nucleic Acid Conformation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Retroviridae; RNA, Small Interfering; Sirolimus; Survival Rate | 2004 |
Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
Topics: Actins; Animals; Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Adhesion; Cell Division; Cell Movement; Cell Transformation, Neoplastic; Cells, Cultured; Chemokine CXCL12; Chemokines, CXC; Chemotaxis; Fibronectins; Fusion Proteins, bcr-abl; Gene Deletion; Genetic Vectors; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Mice; Mutation; Piperazines; Proline; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.
Topics: Benzamides; Cell Line; Cell Line, Tumor; Cell Transformation, Neoplastic; Deoxyglucose; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monosaccharide Transport Proteins; Phloretin; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinases; Pyrimidines; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases; Tyrosine; Up-Regulation | 2005 |
Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL.
Topics: Animals; Benzamides; Cell Line; Cell Transformation, Neoplastic; Electrophoresis, Gel, Two-Dimensional; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Imatinib Mesylate; Mice; Oncogene Proteins, Fusion; Phosphoproteins; Piperazines; Proteome; Pyrimidines; Transfection | 2005 |
Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation.
Topics: Animals; Apoptosis; Benzamides; Bone Marrow Cells; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Gene Expression Regulation, Leukemic; Imatinib Mesylate; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Methionine; Mice; Oncogene Proteins v-abl; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoproteins; Phosphoric Monoester Hydrolases; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; ras Proteins; RNA-Binding Proteins; Signal Transduction | 2005 |
Accessing key steps of human tumor progression in vivo by using an avian embryo model.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Chick Embryo; Disease Models, Animal; Disease Progression; DNA Primers; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glioma; Humans; Imatinib Mesylate; In Situ Hybridization; Oligonucleotide Array Sequence Analysis; Piperazines; Polymerase Chain Reaction; Pyrimidines; Receptor Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Malignant transformation of human cells by constitutive expression of platelet-derived growth factor-BB.
Topics: Animals; Antineoplastic Agents; Becaplermin; Benzamides; Cell Line; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p16; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Inhibitor of Differentiation Protein 1; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Recombinant Fusion Proteins; Repressor Proteins; Transcription Factors; Transcription, Genetic; Vascular Endothelial Growth Factor A | 2005 |
Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation--durable complete remission following imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 9; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; T-Lymphocytes | 2005 |
Characteristic of two mouse bcr-abl-transformed cell lines: I. General properties of the cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cell Line, Transformed; Cell Proliferation; Cell Shape; Cell Transformation, Neoplastic; Cellular Senescence; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Histocompatibility Antigens Class I; Imatinib Mesylate; Leukemia; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Transplantation; Piperazines; Pyrimidines | 2005 |
Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Crystallography, X-Ray; DNA Mutational Analysis; DNA, Neoplasm; Female; Gastrointestinal Stromal Tumors; Germ-Line Mutation; Humans; Imatinib Mesylate; Male; Middle Aged; Models, Chemical; Molecular Sequence Data; Pedigree; Piperazines; Platelet-Derived Growth Factor; Protein Conformation; Proto-Oncogene Proteins c-kit; Pyrimidines | 2005 |
CML clonal evolution with resistance to single agent imatinib therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Transformation, Neoplastic; Clone Cells; Cytarabine; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Treatment Failure; Trisomy | 2005 |
Chronic myelogenous leukemia.
Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chromosome Breakage; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Cytogenetic Analysis; Disease Progression; Drug Interactions; Gene Fusion; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferons; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recombinant Fusion Proteins; Remission Induction; Secondary Prevention; Translocation, Genetic; Transplantation, Homologous | 2005 |
Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Northern; Cell Differentiation; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Female; Imatinib Mesylate; Immunoprecipitation; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mammary Tumor Virus, Mouse; Mice; Mice, Transgenic; Milk Proteins; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Notch4; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Notch; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering | 2007 |
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Topics: Amino Acid Sequence; Animals; Benzamides; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Colony-Forming Units Assay; Disease Models, Animal; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Mutation; Myeloid Progenitor Cells; Phosphotransferases; Phosphotyrosine; Piperazines; Protein Structure, Tertiary; Pyrimidines; Signal Transduction; Substrate Specificity | 2006 |
The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation.
Topics: Benzamides; Cell Line; Cell Transformation, Neoplastic; Humans; Imatinib Mesylate; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-hck; Pyrimidines | 2007 |
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-Associated Death Protein; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Cell Transformation, Neoplastic; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Fetus; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Membrane Proteins; Mice; Myeloid Progenitor Cells; Nitrophenols; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides | 2006 |
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Topics: Animals; Antineoplastic Agents; B-Lymphocytes; Benzamides; Blast Crisis; Burkitt Lymphoma; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
GATA-1 and Gfi-1B interplay to regulate Bcl-xL transcription.
Topics: Apoptosis; Arsenic; bcl-X Protein; Benzamides; Binding Sites; Cell Line; Cell Line, Transformed; Cell Transformation, Neoplastic; Chromatin Immunoprecipitation; Fusion Proteins, bcr-abl; GATA1 Transcription Factor; Gene Expression Regulation; Genes, Reporter; Humans; Imatinib Mesylate; K562 Cells; Luciferases; Piperazines; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins; Pyrimidines; Repressor Proteins; Retroviridae; Transcription, Genetic; Transcriptional Activation | 2007 |
Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
Topics: Amino Acid Substitution; Animals; Antibiotics, Antineoplastic; Benzamides; Cell Proliferation; Cell Transformation, Neoplastic; Cytokines; Drug Resistance, Neoplasm; Enzyme Inhibitors; Hematopoietic Stem Cells; Imatinib Mesylate; Leukemia, Myeloid, Acute; Mastocytosis, Systemic; Mice; Mice, Knockout; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperazines; Protein Subunits; Proto-Oncogene Proteins c-kit; Pyrimidines; rac GTP-Binding Proteins; RAC2 GTP-Binding Protein; Sirolimus | 2007 |
Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells.
Topics: Aneuploidy; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Centrosome; Chromosome Aberrations; Clone Cells; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; U937 Cells | 2007 |
BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
Topics: Antigens, CD34; Benzamides; Cell Adhesion; Cell Proliferation; Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Green Fluorescent Proteins; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcr; Pyrimidines; ras Proteins; Retroviridae; Tyrosine | 2007 |
Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Benzamides; Carcinoma, Hepatocellular; Cell Proliferation; Cell Transformation, Neoplastic; Imatinib Mesylate; Liver Cirrhosis; Liver Neoplasms; Lymphokines; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Receptor, Platelet-Derived Growth Factor alpha; Stromal Cells | 2007 |
Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene.
Topics: Animals; Apoptosis; B-Lymphocytes; bcl-Associated Death Protein; Benzamides; Cell Transformation, Neoplastic; Cells, Cultured; Imatinib Mesylate; Liver; Mice; Mice, Knockout; Oncogene Proteins v-abl; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-pim-1; Pyrimidines; Suppressor of Cytokine Signaling 1 Protein; Suppressor of Cytokine Signaling Proteins | 2008 |
Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Gene Silencing; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiprotein Complexes; Nerve Growth Factor; PC12 Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Receptor, trkA; RNA, Small Interfering; Signal Transduction | 2008 |
The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Becaplermin; Benzamides; Cell Transformation, Neoplastic; Cosmids; Dermatofibrosarcoma; Enzyme Inhibitors; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Oncogene Proteins, Fusion; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Skin Neoplasms | 1999 |
BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis.
Topics: Animals; Benzamides; Cell Movement; Cell Transformation, Neoplastic; Down-Regulation; Fusion Proteins, bcr-abl; Half-Life; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Philadelphia Chromosome; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoric Monoester Hydrolases; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; src Homology Domains | 1999 |
ARG tyrosine kinase activity is inhibited by STI571.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Animals; Benzamides; Binding Sites; Cell Division; Cell Line, Transformed; Cell Transformation, Neoplastic; DNA, Complementary; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Imatinib Mesylate; Mice; Molecular Sequence Data; Neoplasm Proteins; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Protein Kinases; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Fusion Proteins; Sequence Alignment; Sequence Homology, Amino Acid; Transfection | 2001 |
Growth-inhibitory effect of STI571 on cells transformed by the COL1A1/PDGFB rearrangement.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Benzamides; Cell Division; Cell Line, Transformed; Cell Transformation, Neoplastic; Dermatofibrosarcoma; Disease Models, Animal; Gene Rearrangement; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2001 |